ESMO 2023: Will J&J’s Rybrevant Be Able To Scale The Tagrisso Mountain?

Scrip talked to Johnson & Johnson’s vice president of oncology global medical affairs, Mark Wildgust, about how the healthcare giant hopes to plant a flag on Tagrisso’s mountain with its trio of Phase III butterfly-themed studies for the bispecific antibody Rybrevant presented at ESMO.    

Butterfly
• Source: Shutterstock

When the late-breaking abstracts from the European Society for Medical Oncology meeting in Madrid were released early last week, one of the more eagerly pored-over readouts was for Johnson & Johnson’s MARIPOSA study of its bispecific antibody product targeting EGFR and MET, Rybrevant, in non-small cell lung cancer (NSCLC).

The trial is a major part of the US company’s efforts to expand the market for Rybrevant (amivantamab) and challenge...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D